FSTL3

FSTL3 Full Name

follistatin-like 3 (secreted glycoprotein)

FSTL3 Introduction

FSTL3, or Follistatin-like 3, is a secreted glycoprotein that belongs to the follistatin module-containing family. It is also widely recognized by its alternative name, FSRP (Follistatin-related protein). Unlike classical follistatin, FSTL3 possesses a unique structural configuration that includes a Kazal-type serine protease inhibitor domain, in addition to its follistatin domains. This dual-domain architecture suggests that the protein is not merely a passive binding partner but may possess regulatory enzymatic functions. The gene encoding FSTL3 is located on chromosome 19p13 in humans, and its expression is tightly controlled during embryonic development. Its structural homology across vertebrate species underscores its evolutionary importance, pointing to a conserved biological role that extends beyond simple ligand neutralization.

Figure 1. Structure & function of FSTL3.

Pathological Implications and Disease Associations
Dysregulation of FSTL3 expression has been strongly correlated with several human pathologies, including type 2 diabetes, obesity, and polycystic ovary syndrome (PCOS). Elevated circulating levels of FSTL3 are frequently observed in patients with metabolic syndrome, where it may serve as a protective feedback mechanism against excessive activin signaling in inflamed tissues. Moreover, aberrant FSTL3 overexpression has been documented in various malignancies, including colorectal and breast cancers, where it promotes tumor progression by creating a permissive microenvironment through immune modulation and epithelial-mesenchymal transition (EMT). In cardiovascular research, increased FSTL3 has been linked to cardiac hypertrophy, suggesting a dual role as both a stress-responsive factor and a potential contributor to pathological remodeling. These associations have catalyzed interest in FSTL3 as a promising diagnostic biomarker and a plausible therapeutic target.

Current Research Frontiers and Therapeutic Potential
Contemporary investigations are increasingly focused on harnessing FSTL3 for therapeutic benefit, particularly in muscle-wasting disorders and metabolic diseases. Preclinical studies employing neutralizing antibodies or recombinant FSTL3 variants have shown encouraging results in restoring muscle function and improving glycemic control in animal models. However, the challenge remains in achieving tissue-specific modulation, as systemic FSTL3 manipulation could inadvertently disrupt reproductive or bone homeostasis. Cutting-edge research is now exploring the use of antisense oligonucleotides and small-molecule inhibitors to fine-tune FSTL3 expression at the transcriptional level. Furthermore, emerging evidence suggests that FSTL3 may influence neuroinflammatory processes, opening new avenues for its application in neurodegenerative conditions. As structural biology techniques advance, the development of engineered FSTL3 mutants with tailored binding affinities offers a lucrative strategy for next-generation biotherapeutics.

Alternate Names for FSTL3

FSTL3; follistatin-like 3 (secreted glycoprotein); FLRG; FSRP; follistatin-related protein 3; follistatin-like protein 3; follistatin-related gene protein;